Thus, we evaluated the combination of the KRAS<sup>G12C</sup> inhibitor adagrasib with SAM486A in KRAS<sup>G12C</sup>-mutant NSCLC, in vitro and in vivo.<h4>Methods</h4>In vitro assays included viability (MTT), clonogenic, BrdU incorporation, and Western blot analyses across four NSCLC cell lines. Here, KRAS is linked to non-small cell lung carcinoma.